CN103172691B - A kind of medicine material and preparation and purposes - Google Patents
A kind of medicine material and preparation and purposes Download PDFInfo
- Publication number
- CN103172691B CN103172691B CN201310108194.2A CN201310108194A CN103172691B CN 103172691 B CN103172691 B CN 103172691B CN 201310108194 A CN201310108194 A CN 201310108194A CN 103172691 B CN103172691 B CN 103172691B
- Authority
- CN
- China
- Prior art keywords
- cyclovimbuxine
- cyclobuxine
- content
- raw material
- medicine material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to technical field of traditional Chinese medicines, the invention discloses a kind of medicine material and preparation and purposes, wherein medicine material comprises cyclovimbuxine D and Cyclobuxine D. Find by research, in cyclovimbuxine D raw material, within the specific limits, the hepatotoxicity wind agitation of this raw material significantly reduces the content of Cyclobuxine D; Pharmacodynamics test shows, cyclovimbuxine D medicine material of the present invention has the effects such as good treatment angina pectoris, coronary heart disease, arrhythmia cordis.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicines, be specifically related to a kind of cyclovimbuxine D medicine material and preparation and purposes.
Background technology
Buxenine preparation, is the preparation preparing taking Buxaceae plant-little leaf boxwood as raw material, is pioneering the controlling of ChinaTreat cardiovascular and cerebrovascular disease new drug, wherein Buxine Tablet is incorporated into " Chinese pharmacopoeia " 2000 editions, 2005 editions, 2010 editions, above-mentioned medicineThing belongs to traditional Chinese medicine, and traditional Chinese medicine has important effect to the treatment of disease in clinical practice, but traditional Chinese medicine mainly withCompound medicinal material or compound extract are used as medicine, complicated component, and unknown non-quantitation composition occupies significant proportion, exists impurity more,Curative effect material is unclear, quality heterogeneity, unstable, and then cause clinical efficacy unstable, occur to be difficult to look into after bad reactionLook for the problems such as reason, be difficult to adapt to the requirement of modernization and internationalization of Chinese herbal medicines.
Cyclovimbuxine D system extracts the activated monomer-Sheng obtaining from Buxaceae plant little leaf boxwood and congener thereofThing alkali, belongs to derivatives of pregnane, molecular formula: C26H46N20O, pharmacodynamic study shows, cyclovimbuxine D has the obvious enhancing heartMusculotonic effect, there is diastole effect coronarius, there is obvious function of resisting myocardial ischemia, there is anti-arrhythmiaAct on, have the protective effect to cerebral ischemia; Therefore, cyclovimbuxine D is developed to Chinese medicine a kind new medicine significant;Document " research of cyclovimbuxine D hepatotoxicity mechanism ", (cyclovimbuxine D is that Chinese medicine effectively becomes to cyclovimbuxine D raw materialPoint, obtain by method for extraction and purification; According to art methods, all can not obtain absolute 100% material, it must containHave certain impurity component) oral administration has certain hepatotoxicity wind agitation, but in the document not for cyclovimbuxine D raw materialComposition is studied.
Summary of the invention
For these reasons, applicant finds by research, and in cyclovimbuxine D raw material, the content of Cyclobuxine D is oneDetermine in scope (be greater than 0.1% and be less than or equal to 2%), the hepatotoxicity wind agitation of this raw material significantly reduces; Pharmacodynamics test shows, the present inventionCyclovimbuxine D raw material has good treatment angina pectoris, coronary heart disease, ARR effect.
The present invention is achieved through the following technical solutions.
A kind of medicine material, is included as cyclovimbuxine D and Cyclobuxine D, wherein cyclovimbuxine D weight in medicine materialAmount content is for being more than or equal to 98.0% and be less than 100%, and Cyclobuxine D weight content is for being greater than 0.1% and be less than or equal to 2%.
Medicine material described above is preferably: cyclovimbuxine D weight content is for being more than or equal to 99.0% and be less than100%, Cyclobuxine D weight content is for being greater than 0.1% and be less than or equal to 1%.
Medicine material described above is preferably: cyclovimbuxine D weight content is for being more than or equal to 99.5% and be less than100%, Cyclobuxine D weight content is for being greater than 0.1% and be less than or equal to 0.5%.
The pharmaceutical preparation that any medicine material described above is prepared into.
The application of medicine material described in above-mentioned any one in preparation treatment coronary heart diseases and angina pectoris medicine.
The application of medicine material described in above-mentioned any one in preparation treatment antiarrhythmic medicament.
Pharmaceutical preparation described above comprises oral formulations and ejection preparation.
Pharmaceutical preparation described above comprises tablet, capsule, liquid drugs injection, infusion solution or powder-injection.
Liquid drugs injection described above consists of cyclovimbuxine D raw material 1-3 weight portion, trishydroxymethylaminomethane-hydrochloric acidBuffer solution appropriate (adjusting pH=5-6);
Wherein powder-injection consists of cyclovimbuxine D raw material 1-3 weight portion, sweet mellow wine 40-60 weight portion, trihydroxy methyl ammoniaMethylmethane-hydrochloride buffer (adjusting pH=5-6).
Note: in prior art, in Effective Component of Chinese Medicine, content is more than or equal to 80%, is called this material, such as prior artDescribed in " cyclovimbuxine D " be all " cyclovimbuxine D medicine material, its cyclovimbuxine D content is more than or equal to 80% ".
One, hepatotoxicity wind agitation test example
Test example 1
To Mouse Liver toxicity preliminary experiment
Trial drug:
1 group of trial drug: cyclovimbuxine D content 91.9%, Cyclobuxine D content 8.0%, all the other are 0.1% years old.
The preparation method of above-mentioned cyclovimbuxine D raw material is:
Preparative high performance liquid chromatography: mobile phase is 10mmol/L ammonium formate: acetonitrile (8: 92), detects with evaporative light-scatteringDevice detects.
Precision takes about 10mg Control of Cyclovirobuxine D to 25mL measuring bottle, adds 5mL chloroform and dissolves, then use secondNitrile is diluted to scale, as Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL approximately containing ring dimension successively with acetonitrileChinese littleleaf box star D is the Control of Cyclovirobuxine D solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes about 10mg cyclobuxineD reference substance, puts in 25mL measuring bottle, and add chloroform and dissolve and be diluted to scale, as Cyclobuxine D reference substance mother liquor, shouldIt is approximately the Cyclobuxine D contrast of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g containing Cyclobuxine D that mother liquor is diluted to every 1mL successively with acetonitrileProduct solution; Precision measures Control of Cyclovirobuxine D solution, the each 20 μ L of Cyclobuxine D reference substance solution respectively, injects chromatogramInstrument, records retention time.
Sample preparation: get and contain cyclovimbuxine D medicine material (cyclovimbuxine D content is 81.9%), add mobilePhase, dissolves completely, prepares liquid phase post with glycol-based bonded silica gel, according to retention time, intercepts cyclovimbuxine D and cyclobuxineD chromatographic peak solution, concentrate drying, obtains above-mentioned trial drug raw material (all the other in raw material are unknown impuritie).
2 groups of trial drugs: cyclovimbuxine D content 95.9%, Cyclobuxine D content 3.9%, all the other are 0.2% years old.
The preparation method of above-mentioned cyclovimbuxine D raw material is:
Preparative high performance liquid chromatography: mobile phase is 10mmol/L ammonium formate: acetonitrile (8: 92), detects with evaporative light-scatteringDevice detects.
Precision takes about 10mg Control of Cyclovirobuxine D to 25mL measuring bottle, adds 5mL chloroform and dissolves, then use secondNitrile is diluted to scale, as Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL approximately containing ring dimension successively with acetonitrileChinese littleleaf box star D is the Control of Cyclovirobuxine D solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes about 10mg cyclobuxineD reference substance, puts in 25mL measuring bottle, and add chloroform and dissolve and be diluted to scale, as Cyclobuxine D reference substance mother liquor, shouldIt is approximately the Cyclobuxine D contrast of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g containing Cyclobuxine D that mother liquor is diluted to every 1mL successively with acetonitrileProduct solution; Precision measures Control of Cyclovirobuxine D solution, the each 20 μ L of Cyclobuxine D reference substance solution respectively, injects chromatogramInstrument, records retention time.
Sample preparation: get and contain cyclovimbuxine D medicine material (cyclovimbuxine D content is 84.8%), add mobilePhase, dissolves completely, prepares liquid phase post with glycol-based bonded silica gel, according to retention time, intercepts cyclovimbuxine D and cyclobuxineD chromatographic peak solution, concentrate drying, obtains above-mentioned trial drug raw material (all the other in raw material are unknown impuritie).
3 groups of trial drugs: cyclovimbuxine D content 98.4%, Cyclobuxine D content 1.5%, all the other are 0.1% years old.
The preparation method of above-mentioned cyclovimbuxine D raw material is:
Preparative high performance liquid chromatography: mobile phase is 10mmol/L ammonium formate: acetonitrile (8: 92), detects with evaporative light-scatteringDevice detects.
Precision takes about 10mg Control of Cyclovirobuxine D to 25mL measuring bottle, adds 5mL chloroform and dissolves, then use secondNitrile is diluted to scale, as Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL approximately containing ring dimension successively with acetonitrileChinese littleleaf box star D is the Control of Cyclovirobuxine D solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes about 10mg cyclobuxineD reference substance, puts in 25mL measuring bottle, and add chloroform and dissolve and be diluted to scale, as Cyclobuxine D reference substance mother liquor, shouldIt is approximately the Cyclobuxine D contrast of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g containing Cyclobuxine D that mother liquor is diluted to every 1mL successively with acetonitrileProduct solution; Precision measures Control of Cyclovirobuxine D solution, the each 20 μ L of Cyclobuxine D reference substance solution respectively, injects chromatogramInstrument, records retention time.
Sample preparation: get and contain cyclovimbuxine D medicine material (cyclovimbuxine D content is 87.2%), add mobilePhase, dissolves completely, prepares liquid phase post with glycol-based bonded silica gel, according to retention time, intercepts cyclovimbuxine D and cyclobuxineD chromatographic peak solution, concentrate drying, obtains above-mentioned trial drug raw material (all the other in raw material are unknown impuritie).
4 groups of trial drugs: cyclovimbuxine D content 99.1%, Cyclobuxine D content 0.7%, all the other are 0.2% years old.
The preparation method of above-mentioned cyclovimbuxine D raw material is:
Preparative high performance liquid chromatography: mobile phase is 10mmol/L ammonium formate: acetonitrile (8: 92), detects with evaporative light-scatteringDevice detects.
Precision takes about 10mg Control of Cyclovirobuxine D to 25mL measuring bottle, adds 5mL chloroform and dissolves, then use secondNitrile is diluted to scale, as Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL approximately containing ring dimension successively with acetonitrileChinese littleleaf box star D is the Control of Cyclovirobuxine D solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes about 10mg cyclobuxineD reference substance, puts in 25mL measuring bottle, and add chloroform and dissolve and be diluted to scale, as Cyclobuxine D reference substance mother liquor, shouldIt is approximately the Cyclobuxine D contrast of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g containing Cyclobuxine D that mother liquor is diluted to every 1mL successively with acetonitrileProduct solution; Precision measures Control of Cyclovirobuxine D solution, the each 20 μ L of Cyclobuxine D reference substance solution respectively, injects chromatogramInstrument, records retention time.
Sample preparation: get and contain cyclovimbuxine D medicine material (cyclovimbuxine D content is 87.9%), add mobilePhase, dissolves completely, prepares liquid phase post with glycol-based bonded silica gel, according to retention time, intercepts cyclovimbuxine D and cyclobuxineD chromatographic peak solution, concentrate drying, obtains above-mentioned trial drug raw material (all the other in raw material are unknown impuritie).
5 groups of trial drugs: cyclovimbuxine D content 99.5%, Cyclobuxine D content 0.4%, all the other are 0.1% years old.
The preparation method of above-mentioned cyclovimbuxine D raw material is:
Preparative high performance liquid chromatography: mobile phase is 10mmol/L ammonium formate: acetonitrile (8: 92), detects with evaporative light-scatteringDevice detects.
Precision takes about 10mg Control of Cyclovirobuxine D to 25mL measuring bottle, adds 5mL chloroform and dissolves, then use secondNitrile is diluted to scale, as Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL approximately containing ring dimension successively with acetonitrileChinese littleleaf box star D is the Control of Cyclovirobuxine D solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes about 10mg cyclobuxineD reference substance, puts in 25mL measuring bottle, and add chloroform and dissolve and be diluted to scale, as Cyclobuxine D reference substance mother liquor, shouldIt is approximately the Cyclobuxine D contrast of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g containing Cyclobuxine D that mother liquor is diluted to every 1mL successively with acetonitrileProduct solution; Precision measures Control of Cyclovirobuxine D solution, the each 20 μ L of Cyclobuxine D reference substance solution respectively, injects chromatogramInstrument, records retention time.
Sample preparation: get and contain cyclovimbuxine D medicine material (cyclovimbuxine D content is 88.3%), add mobilePhase, dissolves completely, prepares liquid phase post with glycol-based bonded silica gel, according to retention time, intercepts cyclovimbuxine D and cyclobuxineD chromatographic peak solution, concentrate drying, obtains above-mentioned trial drug raw material (all the other in raw material are unknown impuritie).
6 groups of trial drugs: cyclovimbuxine D content 99.8%, Cyclobuxine D content 0.1%, all the other are 0.1% years old.
The preparation method of above-mentioned cyclovimbuxine D raw material is:
Preparative high performance liquid chromatography: mobile phase is 10mmol/L ammonium formate: acetonitrile (8: 92), detects with evaporative light-scatteringDevice detects.
Precision takes about 10mg Control of Cyclovirobuxine D to 25mL measuring bottle, adds 5mL chloroform and dissolves, then use secondNitrile is diluted to scale, as Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL approximately containing ring dimension successively with acetonitrileChinese littleleaf box star D is the Control of Cyclovirobuxine D solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes about 10mg cyclobuxineD reference substance, puts in 25mL measuring bottle, and add chloroform and dissolve and be diluted to scale, as Cyclobuxine D reference substance mother liquor, shouldIt is approximately the Cyclobuxine D contrast of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g containing Cyclobuxine D that mother liquor is diluted to every 1mL successively with acetonitrileProduct solution; Precision measures Control of Cyclovirobuxine D solution, the each 20 μ L of Cyclobuxine D reference substance solution respectively, injects chromatogramInstrument, records retention time.
Sample preparation: get and contain cyclovimbuxine D medicine material (cyclovimbuxine D content is 89.1%), add mobilePhase, dissolves completely, prepares liquid phase post with glycol-based bonded silica gel, according to retention time, intercepts cyclovimbuxine D and cyclobuxineD chromatographic peak solution, concentrate drying, obtains above-mentioned trial drug raw material (all the other in raw material are unknown impuritie).
Above-mentioned trial drug raw material 2g, adds 2000ml water for injection before use, slow with trishydroxymethylaminomethane-hydrochloric acidRush liquid and regulate pH value 5.5, for subsequent use after sterilizing. Blank group, injects water, with isopyknic trishydroxymethylaminomethane-Hydrochloride buffer, mixes completely, for subsequent use.
Experimental animal: KM mouse, male and female half and half, healthy of the right age, body weight 18-22g, in Department Of Medicine, Peking University animal used as testThe heart provides.
Test method: get mouse, male and female half and half, are divided into blank group, trial drug group at random by body weight and sex, everyOrganize 10, mouse tail vein administration, dosage is 0.035mg/kg, blank group gives isopyknic water for injection, continuouslyAdministration 3 days, after 30 minutes, gets the centrifugal 10min of blood 3000r/min in last administration, gets serum, by looking after mutually kit descriptionOperating instruction, measure Serum ALT, AST with automatic biochemistry analyzer, measure ALB, ALP, TBI water with ultraviolet specrophotometerFlat. Get to cut open after blood and get mouse liver and weigh and calculate organ index.
Result of the test: in table 1 and table 2.
The impact of table 1 on mice serum liver function indexes
Note: with relatively * * P < 0.01 of control group, * P < 0.05; Compare #P < 0.05 with 2 groups of tests.
Table 2 is dirty/body ratio result of the test
Note: with relatively * * * P < 0.001 of control group, * * P < 0.01, * P < 0.05; Compare #P < 0.05 with 2 groups of tests.
Test 2
To the hepatotoxic struvite test of mouse
1 group of trial drug: cyclovimbuxine D content 99.4%, Cyclobuxine D content 0.5%, all the other are 0.1% years old.
The preparation method of above-mentioned cyclovimbuxine D raw material is:
Preparative high performance liquid chromatography: mobile phase is 10mmol/L ammonium formate: acetonitrile (8: 92), detects with evaporative light-scatteringDevice detects.
Precision takes about 10mg Control of Cyclovirobuxine D to 25mL measuring bottle, adds 5mL chloroform and dissolves, then use secondNitrile is diluted to scale, as Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL approximately containing ring dimension successively with acetonitrileChinese littleleaf box star D is the Control of Cyclovirobuxine D solution of 1 μ g, 2 μ g, 5 μ g, 10 μ μ g and 20 μ g; Precision takes about 10mg ring Chinese littleleaf boxAlkali D reference substance, puts in 25mL measuring bottle, and add chloroform and dissolve and be diluted to scale, as Cyclobuxine D reference substance mother liquor, willIt is approximately the Cyclobuxine D pair of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g containing Cyclobuxine D that this mother liquor is diluted to every 1mL successively with acetonitrileAccording to product solution; Precision measures Control of Cyclovirobuxine D solution, the each 20 μ L of Cyclobuxine D reference substance solution respectively, injects chromatogramInstrument, records retention time.
Sample preparation: get and contain cyclovimbuxine D medicine material (cyclovimbuxine D content is 88.5%), add mobilePhase, dissolves completely, prepares liquid phase post with glycol-based bonded silica gel, according to retention time, intercepts cyclovimbuxine D and cyclobuxineD chromatographic peak solution, concentrate drying, obtains above-mentioned trial drug raw material (all the other in raw material are unknown impuritie).
2 groups of trial drugs: cyclovimbuxine D content 99.7%, Cyclobuxine D content 0.2%, all the other are 0.1% years old.
The preparation method of above-mentioned cyclovimbuxine D raw material is:
Preparative high performance liquid chromatography: mobile phase is 10mmol/L ammonium formate: acetonitrile (8: 92), detects with evaporative light-scatteringDevice detects.
Precision takes about 10mg Control of Cyclovirobuxine D to 25mL measuring bottle, adds 5mL chloroform and dissolves, then use secondNitrile is diluted to scale, as Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL approximately containing ring dimension successively with acetonitrileChinese littleleaf box star D is the Control of Cyclovirobuxine D solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes about 10mg cyclobuxineD reference substance, puts in 25mL measuring bottle, and add chloroform and dissolve and be diluted to scale, as Cyclobuxine D reference substance mother liquor, shouldIt is approximately the Cyclobuxine D contrast of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g containing Cyclobuxine D that mother liquor is diluted to every 1mL successively with acetonitrileProduct solution; Precision measures Control of Cyclovirobuxine D solution, the each 20 μ L of Cyclobuxine D reference substance solution respectively, injects chromatogramInstrument, records retention time.
Sample preparation: get and contain cyclovimbuxine D medicine material (cyclovimbuxine D content is 88.9%), add mobilePhase, dissolves completely, prepares liquid phase post with glycol-based bonded silica gel, according to retention time, intercepts cyclovimbuxine D and cyclobuxineD chromatographic peak solution, concentrate drying, obtains above-mentioned trial drug raw material (all the other in raw material are unknown impuritie).
3 groups of trial drugs: cyclovimbuxine D content 99.9%, Cyclobuxine D content 0.06%, all the other are 0.04% years old.
The preparation method of above-mentioned cyclovimbuxine D raw material is:
Preparative high performance liquid chromatography: mobile phase is 10mmol/L ammonium formate: acetonitrile (8: 92), detects with evaporative light-scatteringDevice detects.
Precision takes about 10mg Control of Cyclovirobuxine D to 25mL measuring bottle, adds 5mL chloroform and dissolves, then use secondNitrile is diluted to scale, as Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL approximately containing ring dimension successively with acetonitrileChinese littleleaf box star D is the Control of Cyclovirobuxine D solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes about 10mg cyclobuxineD reference substance, puts in 25mL measuring bottle, and add chloroform and dissolve and be diluted to scale, as Cyclobuxine D reference substance mother liquor, shouldIt is approximately the Cyclobuxine D contrast of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g containing Cyclobuxine D that mother liquor is diluted to every 1mL successively with acetonitrileProduct solution; Precision measures Control of Cyclovirobuxine D solution, the each 20 μ L of Cyclobuxine D reference substance solution respectively, injects chromatogramInstrument, records retention time.
Sample preparation: get and contain cyclovimbuxine D medicine material (cyclovimbuxine D content is 89.1%), add mobilePhase, dissolves completely, prepares liquid phase post with glycol-based bonded silica gel, according to retention time, intercepts cyclovimbuxine D and cyclobuxineD chromatographic peak solution, concentrate drying, obtains above-mentioned trial drug raw material (all the other in raw material are unknown impuritie).
Test method: the same.
Result of the test: in table 3 and table 4.
The impact of table 3 on mice serum liver function indexes
Note: with relatively * * P < 0.01 of control group, * P < 0.05; Compare #P < 0.05 with 3 groups of tests.
Table 4 is dirty/body ratio result of the test
Note: with relatively * * P < 0.01 of control group, * P < 0.05; Compare #P < 0.05 with 3 groups of tests.
Conclusion (of pressure testing): above-mentioned test shows, in the time that Cyclobuxine D content is greater than 5% in cyclovimbuxine D raw material, producesHepatotoxicity wind agitation, and Cyclobuxine D content is while being less than 5%, hepatotoxicity wind agitation reduces; In the time that Cyclobuxine D content is less than 2%, hepatotoxicity wind agitationSignificantly reduce, with blank group statistically, there is no difference; Further research shows, Cyclobuxine D content is less thanOr while equaling 0.1%, produce hepatotoxicity wind agitation; Above-mentioned research shows that cyclovimbuxine D weight content is more than or equal to 98.0% and littleIn 100%, Cyclobuxine D weight content is greater than 0.1% and be less than or equal to 2%; Preferably cyclovimbuxine D weight content is greater than etc.In 99.0% and be less than 100%, Cyclobuxine D weight content is greater than 0.1% and be less than or equal to 1%; Further preferably ring dimension is yellowYang Xing D weight content is more than or equal to 99.5% and be less than 100%, and Cyclobuxine D weight content is greater than 0.1% and be less than or equal to0.5%. Absolutely prove that in cyclovimbuxine D raw material, to control Cyclobuxine D significant.
Note: above-mentioned trial drug group also can prepare by the following method:
Get and contain cyclovimbuxine D medicine material (cyclovimbuxine D content is 86.8%), add purified water 30L, stir outstandingFloating, drip concentrated ammonia liquor and regulate pH value to 9-10, drip ammoniacal liquor process and keep system temperature to be no more than 50 DEG C. Add again chloroform extraction3 times, merge organic layer. Add again 0.2mol/LNa2HPO4-0.2mol/L citrate buffer solution (pH7.0), stirs separatory. AbandonOrganic layer, gets under set to 0～4 DEG C of conditions of upper aqueous layer and refrigerates crystallization 24 hours. Filter, filter cake does not need to be dried, and directly enters nextStep.
Get above-mentioned crystallization filter cake, add purified water, stirring suspension, drips concentrated ammonia liquor and regulates pH value to 9.5～11.5 (this stepCan follow the trail of with high-efficient liquid phase technique, determine the content of Cyclobuxine D, thereby adjust pH value), drip ammoniacal liquor process holderBe that temperature is no more than 45 DEG C. Add again chloroform extraction 3 times, merge organic layer. Add anhydrous sodium sulfate, dry, filter filtrate 60DEG C remove below solvent under reduced pressure, obtain white solid and (according to the above-mentioned method of the preparing liquid phase sample of testing, obtain different testsMedicine group sample).
Note: the preparation method of cyclovimbuxine D medicine material of the present invention, can also adopt silica gel column chromatography method to obtainArrive.
Note: cyclovimbuxine D medicine material of the present invention (comprises that cyclovimbuxine D content is greater than 80% and is less than90%) can be purchased from Rui Fensi bio tech ltd, Chengdu.
Two, pharmacological test example
To the protective effect of anesthetized rat myocardial ischemia-reperfusion injury
Experimental animal: healthy SD rat, body weight 240-260g.
Trial drug:
1 group of trial drug: cyclovimbuxine D content 99.7%, Cyclobuxine D content 0.2%, all the other are 0.1% years old.
Above-mentioned trial drug group raw material 2g, adds 2000ml water for injection before use, with trishydroxymethylaminomethane-hydrochloric acidBuffer solution regulates pH value 5.5, for subsequent use after sterilizing. Blank group, injects water, by the amino first of isopyknic trihydroxy methylAlkane-hydrochloride buffer, mixes completely, for subsequent use.
Test reagent: 20% urethane is pressed; The tincture of iodine; Kit; 1%TTC.
Test apparatus: lung ventilator; Electrocardiograph; Ophthalmic tweezers; Automatic clinical chemistry analyzer; Digital camera.
Test method: by rat random packet: blank group, trial drug group. Be placed in the pre-raising of equivalent environment 2 days,Free diet. After pre-raising finishes, test, animal is weighed, and 20% urethane is pressed 0.6ml/100g lumbar injection, waits to anaesthetizeAfter satisfaction, lie on the back and be fixed on mouse plate, trachea cannula, connects lung ventilator, and by 10～12ml tidal volume, the frequency of 70 beats/min givesExhale, continuous positive pressure breathing, inhales: exhale than being 1: 1. Adjust respiration parameter according to respiratory rate and the degree of depth. Connect subsequently electrocardiograph,Survey normal ECG. Cut off front field of operation hair, iodine disinfection, cut off skin, hypodermis, front muscle and manadesma 3～4cm, long along the 3rd intercostal blunt separation intercostal muscle 3cm with 18# vessel forceps, open thoracic cavity and pericardium, recording ecg, struts3,4 ribs, hold Rat Right pleurobranch chamber with left hand four fingers, and assistant upwards pushes away thymus gland with ophthalmic tweezers, at left auricle of heart and pulmonary arteryBetween circular cone, find ligation mark blood vessel great cardiac vein, below left auricle of heart, 2mm place is with wearing without wound roundlet pin band 6-0 silk threadLine, depth of needle is 1～1.5mm, wide 2～3mm, recording ecg after threading, through tail intravenously administrable, dosage is 0.2mg/Kg, recording ecg after administration 10min, and the little plastics pipe pad with groove is at ligation position with one, two rear line heads are tied thereonPrick. At once recording ecg after ligation, is cyanosis or the II S-T section back of a bow that leads with left chamber antetheca and upwards raises and be greater than 0.1mv alsoLasting 0.5h successfully indicates (S-T section is eliminated without changer) above for ligation. 10min recording ecg again after ligation, ligationAfter 30min, cut off ligature, realize and pouring into again, and record pours into electrocardiogram at once, layer-by-layer suture after hematocele in removing thoracic cavity againThe wall of the chest, removes lung ventilator, and animal recovers autonomous respiration, and incision of trachea does not process. Fill with at once again, 10min, 20min, 40min,1h, 2h, 3h recording ecg respectively. Heart is frozen after 10min in refrigerator and cooled, and from the centripetal end of the apex of the heart, parallel coronary sulcus direction will5 of equal thickness are cut in left chamber, put into 1%TTC dye liquor, 37 DEG C of dyeing 10min, and necrotic area is not kermesinus, necrotic areaBe canescence. Digital camera is taken pictures. Weighed respectively in He Fei necrotic area, necrotic area, calculating necrotic area accounts for the percentage of left ventricular massRatio, i.e. infarction size.
Result of the test: the results are shown in Table 5.
The impact of table 5 on rat myocardial infarction model scope
Note: with the comparison of blank group, * P < 0.05, * * P < 0.01.
Test 2
Calcium chloride is brought out to the impact of rat ventricular
Trial drug:
1 group of trial drug: cyclovimbuxine D content 99.5%, Cyclobuxine D content 0.4%, all the other are 0.1% years old.
Above-mentioned trial drug raw material 2g, adds 2000ml water for injection before use, slow with trishydroxymethylaminomethane-hydrochloric acidRush liquid and regulate pH value 5.5, for subsequent use after sterilizing. Blank group, injects water, with isopyknic trishydroxymethylaminomethane-Hydrochloride buffer, mixes completely, for subsequent use.
Experimental technique: Wistar rat, is divided into group at random: control group, trial drug group group. 20% urethane is noted through abdominal cavityPenetrate after anesthesia (1.2mg/kg), dorsal position is fixed, and it is subcutaneous that needle electrode inserts animal foot, the record standard limbs II electrocardio that leadsFigure. If electrocardiogram has ischemic or other Novel presentation, from this experiment, reject. Tail vein is the tested medicine 0.2mg/ of injection slowlyKg, control group waits capacity physiological saline, after administration 10min, in 10s through the complete 2% calcium chloride (140mg/ of tail intravenous injectionKg), arrhythmia cordis time of occurrence, the duration after observation administration.
Result of the test: the results are shown in Table 6.
Table 6 brings out the impact of rat ventricular on calcium chloride
Note: with control group comparison, * P < 0.05, * * P < 0.01.
Preparation Example
Embodiment 1
A kind of medicine material, wherein cyclovimbuxine D weight content is 98.7%, Cyclobuxine D weight content is0.9%, all the other impurity 0.4%.
Above-mentioned raw materials is prepared into liquid drugs injection, infusion solution, powder-injection, tablet, capsule etc.
Wherein liquid drugs injection consists of: cyclovimbuxine D raw material 1g, water for injection 1000ml, trishydroxymethylaminomethane-saltAcid buffer appropriate (adjust pH=5.0); Or cyclovimbuxine D raw material 1g, water for injection 1000ml, citric acid is appropriate (to be adjustedPH value=5.0).
Wherein powder-injection composition: cyclovimbuxine D raw material 1g, water for injection 1000ml, sweet mellow wine 40g, trihydroxy methyl ammoniaMethylmethane-hydrochloride buffer appropriate (adjust pH=5.0); Or cyclovimbuxine D raw material 1g, sweet mellow wine 50g, water for injection1000ml, citric acid appropriate (adjust pH=5.0)
Embodiment 2
A kind of medicine material, wherein cyclovimbuxine D weight content is 99.1%, Cyclobuxine D weight content is0.7%, all the other impurity 0.2%.
Above-mentioned raw materials is prepared into liquid drugs injection, infusion solution, powder-injection, tablet, capsule etc.
Wherein liquid drugs injection consists of: cyclovimbuxine D raw material 2g, water for injection 2000ml, trishydroxymethylaminomethane-saltAcid buffer appropriate (adjust pH=5.5); Or cyclovimbuxine D raw material 2g, water for injection 2000ml, citric acid is appropriate (to be adjustedPH value=5.5).
Wherein powder-injection composition: cyclovimbuxine D raw material 2g, water for injection 2000ml, sweet mellow wine 50g, trihydroxy methyl ammoniaMethylmethane-hydrochloride buffer appropriate (adjust pH=5.5); Or cyclovimbuxine D raw material 2g, sweet mellow wine 50g, water for injection2000ml, citric acid appropriate (adjust pH=5.5)
Embodiment 3
A kind of medicine material, wherein cyclovimbuxine D weight content is 99.3%, Cyclobuxine D weight content is0.5%, all the other impurity 0.2%.
Above-mentioned raw materials is prepared into liquid drugs injection, infusion solution, powder-injection, tablet, capsule etc.
Wherein liquid drugs injection consists of: cyclovimbuxine D raw material 2g, water for injection 2000ml, trishydroxymethylaminomethane-saltAcid buffer appropriate (adjust pH=5.5); Or cyclovimbuxine D raw material 2g, water for injection 2000ml, citric acid is appropriate (to be adjustedPH value=5.5).
Wherein powder-injection composition: cyclovimbuxine D raw material 2g, water for injection 2000ml, sweet mellow wine 50g, trihydroxy methyl ammoniaMethylmethane-hydrochloride buffer appropriate (adjust pH=5.5); Or cyclovimbuxine D raw material 2g, sweet mellow wine 50g, water for injection2000ml, citric acid appropriate (adjust pH=5.5)
Embodiment 4
A kind of medicine material, wherein cyclovimbuxine D weight content is 99.7%, Cyclobuxine D weight content is0.2%, all the other impurity 0.1%.
Above-mentioned raw materials is prepared into liquid drugs injection, infusion solution, powder-injection, tablet, capsule etc.
Wherein liquid drugs injection consists of: cyclovimbuxine D raw material 2g, water for injection 2000ml, trishydroxymethylaminomethane-saltAcid buffer appropriate (adjust pH=5.5); Or cyclovimbuxine D raw material 2g, water for injection 2000ml, citric acid is appropriate (to be adjustedPH value=5.5).
Wherein powder-injection composition: cyclovimbuxine D raw material 2g, water for injection 2000ml, sweet mellow wine 50g, trihydroxy methyl ammoniaMethylmethane-hydrochloride buffer appropriate (adjust pH=5.5); Or cyclovimbuxine D raw material 2g, sweet mellow wine 50g, water for injection2000ml, citric acid appropriate (adjust pH=5.5).
Embodiment 5
A kind of medicine material, wherein cyclovimbuxine D weight content is 99.0%, Cyclobuxine D weight content is0.8%, all the other impurity 0.2%.
Above-mentioned raw materials is prepared into liquid drugs injection, infusion solution, powder-injection, tablet, capsule etc.
Wherein liquid drugs injection consists of: cyclovimbuxine D raw material 2g, water for injection 2000ml, trishydroxymethylaminomethane-saltAcid buffer appropriate (adjust pH=5.5); Or cyclovimbuxine D raw material 2g, water for injection 2000ml, citric acid is appropriate (to be adjustedPH value=5.5).
Wherein powder-injection composition: cyclovimbuxine D raw material 2g, water for injection 2000ml, sweet mellow wine 50g, trihydroxy methyl ammoniaMethylmethane-hydrochloride buffer appropriate (adjust pH=5.5); Or cyclovimbuxine D raw material 2g, sweet mellow wine 50g, water for injection2000ml, citric acid appropriate (adjust pH=5.5).
Embodiment 6
A kind of medicine material, wherein cyclovimbuxine D weight content is 99.7%, Cyclobuxine D weight content is0.2%, all the other impurity 0.1%.
Above-mentioned raw materials is prepared into liquid drugs injection, infusion solution, powder-injection, tablet, capsule etc.
Wherein liquid drugs injection consists of: cyclovimbuxine D raw material 2g, water for injection 2000ml, trishydroxymethylaminomethane-saltAcid buffer appropriate (adjust pH=5.5); Or cyclovimbuxine D raw material 2g, water for injection 2000ml, citric acid is appropriate (to be adjustedPH value=5.5).
Wherein powder-injection composition: cyclovimbuxine D raw material 2g, water for injection 2000ml, sweet mellow wine 50g, trihydroxy methyl ammoniaMethylmethane-hydrochloride buffer appropriate (adjust pH=5.5); Or cyclovimbuxine D raw material 2g, sweet mellow wine 50g, water for injection2000ml, citric acid appropriate (adjust pH=5.5).
Preparation Example includes but not limited to above-mentioned.
Claims (6)
1. a medicine material, is characterized in that medicine material comprises cyclovimbuxine D and Cyclobuxine D, wherein ring dimension Chinese littleleaf boxStar D content 98.4%, Cyclobuxine D content 1.5%, all the other are 0.1% years old; Or cyclovimbuxine D content 99.1%, cyclobuxineD content 0.7%, all the other are 0.2% years old; Or cyclovimbuxine D content 99.4%, Cyclobuxine D content 0.5%, all the other are 0.1% years old;Or cyclovimbuxine D content 99.7%, Cyclobuxine D content 0.2%, all the other are 0.1% years old.
2. a kind of medicine material according to claim 1, is characterized in that medicine material is prepared into pharmaceutical preparation.
3. the application of medicine material according to claim 1 in preparation treatment coronary heart diseases and angina pectoris medicine.
4. the application of medicine material according to claim 1 in preparation treatment antiarrhythmic medicament.
5. a kind of medicine material according to claim 2, wherein pharmaceutical preparation comprises oral formulations and ejection preparation.
6. a kind of medicine material according to claim 2, wherein pharmaceutical preparation comprises tablet, capsule, liquid drugs injection, transfusionAgent or powder-injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310108194.2A CN103172691B (en) | 2013-04-01 | 2013-04-01 | A kind of medicine material and preparation and purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310108194.2A CN103172691B (en) | 2013-04-01 | 2013-04-01 | A kind of medicine material and preparation and purposes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103172691A CN103172691A (en) | 2013-06-26 |
| CN103172691B true CN103172691B (en) | 2016-05-25 |
Family
ID=48632941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310108194.2A Active CN103172691B (en) | 2013-04-01 | 2013-04-01 | A kind of medicine material and preparation and purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103172691B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112521440B (en) * | 2020-05-25 | 2021-08-20 | 南京经皮科技有限公司 | Method for purifying cyclochrysine D |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814616A (en) * | 2006-03-13 | 2006-08-09 | 杭太俊 | Buxine, buxine hydrochloride, and its preparing method and formulation |
-
2013
- 2013-04-01 CN CN201310108194.2A patent/CN103172691B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814616A (en) * | 2006-03-13 | 2006-08-09 | 杭太俊 | Buxine, buxine hydrochloride, and its preparing method and formulation |
Non-Patent Citations (1)
| Title |
|---|
| 黄杨宁原料中生物碱的分离与鉴定;刘洁等;《中草药》;20061130;第37卷(第11期);第1614-1618页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103172691A (en) | 2013-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104274518B (en) | A kind of Chinese medicine composition and preparation | |
| CN100490795C (en) | Red sage root salvianolic acid A injection formulation for treating cardiovascular diseases and preparation process thereof | |
| JP6906307B2 (en) | Chinese herbal medicine compositions, their formulations and uses | |
| CN100569219C (en) | A kind of pharmaceutical composition that is used for oral formulations and preparation method thereof | |
| US20150025030A1 (en) | Hydroxysafflor yellow A sodium and preparation as well as application thereof | |
| CN101311160B (en) | Method for preparing red sage root salviandic acid A | |
| CN101230003B (en) | Preparation method of salvia miltiorrhiza tanshinoate A | |
| WO2018133563A1 (en) | Panax plant extract and pharmaceutical composition and use thereof | |
| CN1689575B (en) | Application of ocotillol in the preparing process of medicine for treating or preventing cardiovascular and cerebrovascular disease | |
| CN105078909A (en) | Cisatracurium besilate freeze dried composition for injection and preparation method thereof | |
| CN102274260B (en) | Medicinal composition of notoginseng root extract and preparation method thereof | |
| CN103172691B (en) | A kind of medicine material and preparation and purposes | |
| CN101006984B (en) | An injection preparation containing salvianolic acid A and extract of panax natoginseng, and its preparation method and application | |
| CN101759672A (en) | Salvianolic acid B in radix salviae miltiorrhizae | |
| CN101518509A (en) | Oral drug combination containing salvianolic acid A | |
| CN101006975B (en) | An oral medicine preparation containing salvianolic acid A and extract of panax natoginseng, and its preparation method and application | |
| CN103172692B (en) | A kind of medicine material and preparation and purposes | |
| CN1857385B (en) | Medicine composition for treating cervical spondylosis and its preparing method | |
| CN104173358B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN102266386B (en) | Scutellaria baicalensis extract and preparation method and uses thereof | |
| CN106727498A (en) | Treat the composition and its preparation and the method for inspection of cardiovascular and cerebrovascular disease | |
| CN103191131B (en) | Traditional Chinese medicine raw material as well as preparation and use thereof | |
| CN103191130B (en) | Traditional Chinese medicine raw material as well as preparation and use thereof | |
| CN101019878B (en) | Injection medicine composite containing salvianolic acid A and its preparation | |
| CN101759751A (en) | Ginsenoside Rg 1 containing ginsenoside Re impurity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 100098 Beijing city Haidian District No. 48 Zhichun Road Yingdu building C-4-15A Applicant after: Tibet Yiming Xiya Biological Medical Technology Co., Ltd. Address before: 100098 Beijing city Haidian District No. 48 Zhichun Road Yingdu building B block 22 layer Applicant before: Tibet Yiming Xiya Biological Medical Technology Co., Ltd. |
|
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Lin Qionggang 850000 Lhasa Road, Tibet autonomous region economic and Technological Development Zone Applicant after: XIZANG YIMING XIYA PHARMACEUTICAL TECHNOLOGY CO., LTD. Address before: 100098 Beijing city Haidian District No. 48 Zhichun Road Yingdu building C-4-15A Applicant before: Tibet Yiming Xiya Biological Medical Technology Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TIBET YIMING XIYA BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. TO: XIZANG YIMING XIYA PHARMACEUTICAL TECHNOLOGY CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: Lin Qionggang road Lhasa 850000 Tibet autonomous region economic and Technological Development Zone No. 6 Patentee after: XIZANG YIMING XIYA PHARMACEUTICAL TECHNOLOGY CO., LTD. Address before: Lin Qionggang 850000 Lhasa Road, Tibet autonomous region economic and Technological Development Zone Patentee before: XIZANG YIMING XIYA PHARMACEUTICAL TECHNOLOGY CO., LTD. |